Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808055 | 0.91 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL6895094 | 0.84 | LTB4R (0.84) | LTB4RLTB4R2 | |
| SCHEMBL6803447 | 0.82 | LTB4R (0.71) | LTB4RLTB4R2 | |
| Etalocib SCHEMBL4306317 | 0.82 | LTB4R (0.83) | LTB4RLTB4R2 | |
| SCHEMBL6804099 | 0.81 | LTB4R (0.70) | LTB4RLTB4R2 | |
| SCHEMBL8949561 | 0.81 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL6804105 | 0.80 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL8949579 | 0.80 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL6807001 | 0.77 | LTB4R (0.66) | LTB4RLTB4R2 | |
| SCHEMBL9075395 | 0.76 | LTB4R (1.00) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198779-A1 | Heterocycle substituted diphenyl leukotriene antagonists | SAWYER JASON SCOTT (US) | 2004-10-07 | — | — | US | disclosed |
| US-6797723-B1 | Heterocycle substituted diphenyl leukotriene antagonists | ELI LILLY AND COMPANY | 2004-09-28 | — | — | US | disclosed |
| EP-1263743-A1 | HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-1231939-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1231938-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034198-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034580-A1 | HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034137-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034135-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198779-A1 | Heterocycle substituted diphenyl leukotriene antagonists | LTB4R, LTB4R2, LTA4H | LTB4R 1/4885LTB4R2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.